These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28181841)

  • 1. Surface density of polyarginine influence the size, zeta potential, cellular uptake and tissue distribution of the nanostructured lipid carrier.
    Sun M; Zhu Z; Wang H; Han C; Liu D; Tian L; Yang X; Pan W
    Drug Deliv; 2017 Nov; 24(1):519-526. PubMed ID: 28181841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyarginine and PEG-AEYLR comodified nanostructured lipid carrier: 10mol% uncleavable PEG-AEYLR showed no shielding effect to polyarginine in vitro while maintaining good tumor targeting in vivo.
    Sun M; Zhu Z; Wang H; Jin S; Yang X; Han C; Pan W
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):284-292. PubMed ID: 28355889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
    Yang Y; Xie X; Yang Y; Zhang H; Mei X
    J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
    Li F; Weng Y; Wang L; He H; Yang J; Tang X
    Int J Pharm; 2010 Jun; 393(1-2):203-11. PubMed ID: 20385221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells.
    Zhang YL; Zhang ZH; Jiang TY; Ayman-Waddad ; Jing-Li ; Lv HX; Zhou JP
    Pharmazie; 2013 Jan; 68(1):47-53. PubMed ID: 23444780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
    Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
    Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema.
    Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K
    Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556
    [No Abstract]   [Full Text] [Related]  

  • 8. Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment.
    Huang R; Li J; Kebebe D; Wu Y; Zhang B; Liu Z
    Drug Deliv; 2018 Nov; 25(1):757-765. PubMed ID: 29528244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
    Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
    Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
    Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
    Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.
    Pinheiro M; Ribeiro R; Vieira A; Andrade F; Reis S
    Drug Des Devel Ther; 2016; 10():2467-75. PubMed ID: 27536067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic
    Sun M; Gao Y; Zhu Z; Wang H; Han C; Yang X; Pan W
    Asian J Pharm Sci; 2017 Jan; 12(1):51-58. PubMed ID: 32104313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology.
    Zhang W; Li X; Ye T; Chen F; Sun X; Kong J; Yang X; Pan W; Li S
    Int J Pharm; 2013 Sep; 454(1):354-66. PubMed ID: 23876384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
    Liu Y; Pan J; Feng SS
    Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
    Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
    Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
    Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
    Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
    Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
    Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redox sensitive PEG controlled octaarginine and targeting peptide co-modified nanostructured lipid carriers for enhanced tumour penetrating and targeting in vitro and in vivo.
    Wang H; Sun M; Li D; Yang X; Han C; Pan W
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):313-322. PubMed ID: 28362124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.
    Emami J; Rezazadeh M; Sadeghi H; Khadivar K
    Pharm Dev Technol; 2017 May; 22(3):370-382. PubMed ID: 27689412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.